DK0540599T3 - Adoptiv immunterapi med interleukin-7 - Google Patents
Adoptiv immunterapi med interleukin-7Info
- Publication number
- DK0540599T3 DK0540599T3 DK91913422T DK91913422T DK0540599T3 DK 0540599 T3 DK0540599 T3 DK 0540599T3 DK 91913422 T DK91913422 T DK 91913422T DK 91913422 T DK91913422 T DK 91913422T DK 0540599 T3 DK0540599 T3 DK 0540599T3
- Authority
- DK
- Denmark
- Prior art keywords
- lymphoid cells
- interleukin
- individual
- specific antigen
- adoptive immunotherapy
- Prior art date
Links
- 108010002586 Interleukin-7 Proteins 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 102000000704 Interleukin-7 Human genes 0.000 title 1
- 229940100994 interleukin-7 Drugs 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/559,001 US5229115A (en) | 1990-07-26 | 1990-07-26 | Adoptive immunotherapy with interleukin-7 |
PCT/US1991/004919 WO1992001459A1 (en) | 1990-07-26 | 1991-07-12 | Adoptive immunotherapy with interleukin-7 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0540599T3 true DK0540599T3 (da) | 1998-08-24 |
Family
ID=24231881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK91913422T DK0540599T3 (da) | 1990-07-26 | 1991-07-12 | Adoptiv immunterapi med interleukin-7 |
Country Status (16)
Country | Link |
---|---|
US (1) | US5229115A (ja) |
EP (1) | EP0540599B1 (ja) |
JP (1) | JP3825467B2 (ja) |
AT (1) | ATE161180T1 (ja) |
AU (1) | AU646881B2 (ja) |
CA (1) | CA2087525C (ja) |
DE (1) | DE69128476T2 (ja) |
DK (1) | DK0540599T3 (ja) |
ES (1) | ES2112860T3 (ja) |
FI (1) | FI105045B (ja) |
GR (1) | GR3026358T3 (ja) |
IE (1) | IE912486A1 (ja) |
IL (1) | IL98957A (ja) |
NO (1) | NO930243D0 (ja) |
NZ (1) | NZ239113A (ja) |
WO (1) | WO1992001459A1 (ja) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
US5728388A (en) * | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US5474769A (en) * | 1991-03-08 | 1995-12-12 | Sterling Winthrop Inc. | Treatment of microbial infection by monocyte stimulation with interleukin-7 |
CA2157379A1 (en) * | 1993-03-02 | 1994-09-15 | David S. Terman | Method of cancer treatment |
US20020127201A1 (en) * | 1994-07-01 | 2002-09-12 | Dana-Farber Cancer Institute. | Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain |
US6576236B1 (en) * | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
US20020182730A1 (en) * | 1995-07-26 | 2002-12-05 | Micheal L. Gruenberg | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
US5627070A (en) * | 1995-07-26 | 1997-05-06 | Celltherapy, Inc. | Cell growing device for in vitro cell population expansion |
DK0879282T3 (da) | 1996-01-17 | 2003-10-20 | Imp College Innovations Ltd | Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL) |
FR2745185B1 (fr) * | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
EP0930887B1 (en) * | 1996-10-11 | 2002-12-18 | The Regents of the University of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
US5981472A (en) * | 1997-02-21 | 1999-11-09 | Dx/Ibr Corporation | Methods for treating diseases |
JP4741074B2 (ja) | 1998-02-24 | 2011-08-03 | シスターズ オブ プロビデンス イン オレゴン | Ox−40レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法 |
US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
BR0207399A (pt) | 2001-02-20 | 2004-10-26 | Ortho Mcneil Pharm Inc | Método de terapia com células para o tratamento de tumores |
US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
FR2821947B1 (fr) * | 2001-03-12 | 2003-05-16 | Canon Kk | Procede et dispositif de validation de parametres definissant une image |
DE10132502A1 (de) * | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen |
US20030134341A1 (en) * | 2001-09-19 | 2003-07-17 | Medcell Biologics, Llc. | Th1 cell adoptive immunotherapy |
US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
AU2002366044A1 (en) * | 2001-11-22 | 2003-06-10 | Medigenes | Interleukin-2 gene transferred lymphokine activated killer cells |
US20030175272A1 (en) * | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
WO2007047764A2 (en) | 2005-10-17 | 2007-04-26 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
US20080081031A1 (en) | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
US20080089875A1 (en) * | 2006-10-13 | 2008-04-17 | Zheng Cui | Methods and compositions for the treatment of cancer |
WO2010063865A1 (es) | 2008-12-03 | 2010-06-10 | Proyecto De Biomedicina Cima, S.L. | Uso de modulinas solubles en fenol para el desarrollo de vacunas |
WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性wt1ペプチド及びその使用方法 |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
CA2898099A1 (en) | 2013-01-15 | 2014-07-24 | David A. Scheinberg | Immunogenic wt-1 peptides and methods of use thereof |
CA2902448C (en) | 2013-03-01 | 2023-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
BR112015026122A8 (pt) | 2013-04-18 | 2020-01-21 | Armo Biosciences Inc | agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit |
US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションLycera Corporation | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
CA2947290A1 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
WO2016064817A1 (en) | 2014-10-22 | 2016-04-28 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
WO2016179343A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
AU2016268403A1 (en) | 2015-05-28 | 2017-12-07 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
EP3341012A4 (en) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
US20210379106A1 (en) * | 2018-06-14 | 2021-12-09 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for enhancing car t cell function |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4902288A (en) * | 1985-12-03 | 1990-02-20 | Marylou Ingram | Implantable immunotherapy system using stimulated cells |
US4965195A (en) * | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US5041289A (en) * | 1987-11-13 | 1991-08-20 | Becton Dickinson And Company | Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells |
AU3183089A (en) * | 1988-02-11 | 1989-09-06 | Board Of Regents, The University Of Texas System | Improved method for treatment of cancer with activated oncolytic leukocytes |
US5032396A (en) * | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
-
1990
- 1990-07-26 US US07/559,001 patent/US5229115A/en not_active Expired - Lifetime
-
1991
- 1991-07-12 EP EP91913422A patent/EP0540599B1/en not_active Expired - Lifetime
- 1991-07-12 WO PCT/US1991/004919 patent/WO1992001459A1/en active IP Right Grant
- 1991-07-12 DE DE69128476T patent/DE69128476T2/de not_active Expired - Lifetime
- 1991-07-12 JP JP51267991A patent/JP3825467B2/ja not_active Expired - Lifetime
- 1991-07-12 AT AT91913422T patent/ATE161180T1/de not_active IP Right Cessation
- 1991-07-12 CA CA002087525A patent/CA2087525C/en not_active Expired - Lifetime
- 1991-07-12 AU AU82872/91A patent/AU646881B2/en not_active Expired
- 1991-07-12 ES ES91913422T patent/ES2112860T3/es not_active Expired - Lifetime
- 1991-07-12 DK DK91913422T patent/DK0540599T3/da active
- 1991-07-16 IE IE248691A patent/IE912486A1/en not_active IP Right Cessation
- 1991-07-24 NZ NZ239113A patent/NZ239113A/en not_active IP Right Cessation
- 1991-07-25 IL IL9895791A patent/IL98957A/xx not_active IP Right Cessation
-
1993
- 1993-01-19 FI FI930206A patent/FI105045B/fi not_active IP Right Cessation
- 1993-01-25 NO NO930243A patent/NO930243D0/no unknown
-
1998
- 1998-03-13 GR GR980400543T patent/GR3026358T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
NO930243L (no) | 1993-01-25 |
WO1992001459A1 (en) | 1992-02-06 |
JPH05509093A (ja) | 1993-12-16 |
DE69128476D1 (de) | 1998-01-29 |
FI930206A (fi) | 1993-01-19 |
FI105045B (fi) | 2000-05-31 |
NO930243D0 (no) | 1993-01-25 |
AU8287291A (en) | 1992-02-18 |
AU646881B2 (en) | 1994-03-10 |
IE912486A1 (en) | 1992-01-29 |
GR3026358T3 (en) | 1998-06-30 |
DE69128476T2 (de) | 1998-07-23 |
FI930206A0 (fi) | 1993-01-19 |
EP0540599B1 (en) | 1997-12-17 |
EP0540599A1 (en) | 1993-05-12 |
ES2112860T3 (es) | 1998-04-16 |
IL98957A0 (en) | 1992-07-15 |
JP3825467B2 (ja) | 2006-09-27 |
NZ239113A (en) | 1997-07-27 |
CA2087525C (en) | 2006-05-30 |
IL98957A (en) | 2000-11-21 |
US5229115A (en) | 1993-07-20 |
CA2087525A1 (en) | 1992-01-27 |
ATE161180T1 (de) | 1998-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0540599T3 (da) | Adoptiv immunterapi med interleukin-7 | |
FI953731A (fi) | Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa | |
SE8005256L (sv) | Framstellningsforfarande | |
ATE296875T1 (de) | Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen | |
DE69333433D1 (de) | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung | |
SE8000243L (sv) | Typ ii-interferon och medel innehallande detsamma | |
DE69028320D1 (de) | Illudin-analoge, verwendet als antitumormittel | |
DK372780A (da) | Fremgangsmaade til propagering af humant hepatitis a virus | |
ATE15693T1 (de) | Zellkultur-verfahren. | |
Rees et al. | Immune response to adenovirus 12-induced tumour antigens, as measured in vitro by the macrophage migration inhibition test | |
NO922422D0 (no) | Matrise med adherent bundede celler, samt fremgangsmaate ved fremstilling av virus/virusantigener | |
DK0538330T3 (da) | Beta-Alethin-anvendelse til celledyrkning og terapi | |
ES8604774A1 (es) | Procedimiento de preparar agentes cosmeticos para el trata- miento de la piel | |
PT72015B (en) | Process for preparing "invitro" cultures of hepatitis b virus | |
Law et al. | A unique tumor rejection antigen from the S91 murine malignant melanoma | |
Wilkinson | A note on the use of Stuart's transport medium for the isolation of the Gonococcus | |
SE8005921L (sv) | Nya foreningar med karcinostatisk och immunostimulerande aktivitet samt forfarande for framstellning derav | |
Bilsel et al. | Effect of defibrotide and endothelial cell growth supplement on human endothelial cells in culture | |
SU549106A1 (ru) | Способ сохранени отдаленных гибридов | |
Chippaux et al. | Stability of freeze-dried tissue culture rabies vaccine for human use | |
Nishida et al. | Suppression of cellular immunity due to inhibition of purine nucleoside phosphorylase by allopurinol-riboside | |
Abe | Establishment of a hamster lymphoma cell line | |
Ozato et al. | Transfer of concanavalin A between responding lymphocytes and syngeneic stimulating cells in cell-mediated mitogenic response | |
Fridenshteĭn et al. | The humoral nature of the colony-stimulating action of bone marrow cells on stromal colony formation in bone marrow cultures | |
Vilcek | CELL SUBSTRATES FOR BIOLOGICALS OTHER THAN VACCINES |